EFTA00603571.pdf

Science recently learned —50% of medications work Imagine a world in which we could through GPCR signaling. target-design medications to signal through specific GPCR channels. But, 99% of existing drugs were discovered by luck: trial, error, observation and testing, over years. It would change medicin OH,Laboratories Re-engineering Drug Discovery The ability to produce stable water-soluble protein replicants Company Structure is a fundamental new tool that opens many doors: OH2 is an IP development and holding company, structured to form subsidiaries to monetize the Drug Discovery benefits our technologies bring to a range of fields: Our technology provides a critical revitalization of drying pharma pipelines: (i) Addresses compounds with poor solubili- • Drug Discovery ty (over 40% of drugs) offering increased efficacy and faster, • Research Tools cheaper development. (ii) Enables novel drug candidates for • Diagnostics GPCR-mediated diseases: • mAB-Similar Products *Examples include: • Autoimmune/Allergy Therapy Alzheimer's (GPR3) Parkinson's (GPCR 37) Prostate cancer (GPR68/0GRI) • Viral Therapeutics Arteriosclerosis (GPRS 176) Asthma (CCR3.CXCR2) Cancer metastasis (CXCR4) Colon cancer (MA51) Ovarian Cancer (OCRI) Leukemia (P2Y8/P2 R Y8) • Molecular Sensors Diabetes (GPCR 21) Autism (GPCR 63) Bipolar disorder (GPRS 78) Osteoarthritis (GPR22) Lung cancer (GPR87) Breast Cancer (CXCR4) Market Size (Pharma only) (Plus over 700 others and the list grows almost daily.) GPCR-related pharma is —$425B/year globally. Research Tools - Provide our synthetic GPCRQTY materials, Our technology will grow the market considerably. duplicating native GPCR functionality in a water-soluble form to research laboratories. Our Scientists Shuguang Zhang, Ph.D - Lead Investigator Diagnostics - Water-soluble GPCRQTY materials maintain ligand MIT Researcher for 26 years binding ability to specific antigens/receptors, providing a new 160 papers, 36 patents issued and pending Last company (3DMatrix) valued at 5800M class of novel, low-cost diagnostics. Prof. Robert Langer mAB-Similar Products - New molecular therapeutics: (i) MIT Professor for 36 years 1,250+ articles. 220+ major awards Target-designed to be similar to monoclonal antibodies, but 1,030+ patents. 250+ licenses easier to produce; (ii) Engineering mAbQTY to reduce mAb Alexander Rich, M.D. aggregation and increase long-term storage. MIT Professor for 56 years 550+ articles. Many awards and honors Autoimmune/Allergy Therapy - Use GPCRQTY as decoy treat- David Jin, M.D. ment (similar to Enbrel/Etanercept), theoretically for any disease Practicing Oncologist and Researcher or condition associated with GPCR signaling. 2012 Top Chief Medical Officer in America 2014 Leading Physicians in the World Viral Therapeutics - Use Receptors QTY to trap viruses including: Our Board HIV, Ebola, Marburg & Lassa - for rapid reduction of viral loads. David Levy, Ph.D - General Manager and Chairman Marc Rioult, Ph.D - Man. Director, 3DMatrix US & Europe Molecular Sensors - Use Receptors QTY to create ultra-sensitive Kevin Munnelly, Ph.D - President and CEO, Gen9 bionic detectors. (e.g. a chip-based bionic nose.) Steve Yang, Ph.D. - Director, Sentilia For more information contact David Levy EFTA00603571